181 related articles for article (PubMed ID: 19531657)
1. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
[TBL] [Abstract][Full Text] [Related]
2. [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
Jiang Q; Qin Y; Lai Y; Jiang H; Shi H
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):7-13. PubMed ID: 26876246
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Efficacy and Safety of Flumatinib in the Treatment of Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase].
Li Q; Jing L; Wu PQ; Han LY; Xing HY; Huang CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387893
[TBL] [Abstract][Full Text] [Related]
6. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
Crisan AM; Coriu D; Arion C; Colita A; Jardan C
J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
[TBL] [Abstract][Full Text] [Related]
7. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Jain N; Reuben JM; Kantarjian H; Li C; Gao H; Lee BN; Cohen EN; Ebarb T; Scheinberg DA; Cortes J
Cancer; 2009 Sep; 115(17):3924-34. PubMed ID: 19536894
[TBL] [Abstract][Full Text] [Related]
8. [Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
Zhao HF; Zhang Y; Li Z; Zhou J; Zu YL; Yu FK; Gui RR; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):540-545. PubMed ID: 30122011
[No Abstract] [Full Text] [Related]
9. A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors.
Gandhe N; Vekaria M; Dabak V
Cureus; 2021 Aug; 13(8):e16914. PubMed ID: 34513487
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
Nevejan L; Labarque V; Boeckx N
Eur J Haematol; 2024 Mar; 112(3):458-465. PubMed ID: 37985225
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Gambacorti-Passerini C; Kantarjian HM; Kim DW; Khoury HJ; Turkina AG; Brümmendorf TH; Matczak E; Bardy-Bouxin N; Shapiro M; Turnbull K; Leip E; Cortes JE
Am J Hematol; 2015 Sep; 90(9):755-68. PubMed ID: 26040495
[TBL] [Abstract][Full Text] [Related]
12. Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival.
Romero-Morelos P; González-Yebra AL; Herrerías-García A; Ruíz-Velázquez FA; Bueno-Rosario LJ; González-Yebra B
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790196
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients.
Towachiraporna S; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Tantiworawit A
Asian Pac J Cancer Prev; 2023 May; 24(5):1513-1520. PubMed ID: 37247270
[TBL] [Abstract][Full Text] [Related]
14. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
[TBL] [Abstract][Full Text] [Related]
15. [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].
Li YY; Wang CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387894
[TBL] [Abstract][Full Text] [Related]
16. A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
Zhao ZY; Tang N; Lin LE
Leuk Res; 2023 Oct; 133():107369. PubMed ID: 37660636
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Horne GA; Stobo J; Kelly C; Mukhopadhyay A; Latif AL; Dixon-Hughes J; McMahon L; Cony-Makhoul P; Byrne J; Smith G; Koschmieder S; BrÜmmendorf TH; Schafhausen P; Gallipoli P; Thomson F; Cong W; Clark RE; Milojkovic D; Helgason GV; Foroni L; Nicolini FE; Holyoake TL; Copland M
Leukemia; 2020 Jul; 34(7):1775-1786. PubMed ID: 31925317
[TBL] [Abstract][Full Text] [Related]
18. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M; Alcazer V; Etienne G; Huguet F; Berger M; Cayssials E; Charbonnier A; Escoffre-Barbe M; Johnson-Ansah H; Legros L; Roy L; Delmer A; Ianotto JC; Orvain C; Larosa F; Meunier M; Amé S; Andreoli A; Cony-Makhoul P; Morisset S; Tigaud I; Rea D; Nicolini FE
Leuk Res; 2023 Jul; 130():107308. PubMed ID: 37230027
[TBL] [Abstract][Full Text] [Related]
19. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Short NJ; Senapati J; Jabbour E
Curr Hematol Malig Rep; 2023 Dec; 18(6):234-242. PubMed ID: 37651057
[TBL] [Abstract][Full Text] [Related]
20. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
